Immune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control?

Antonio Bertoletti; Adam J Gehring

doi:10.1371/journal.ppat.1003784

Immune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control?

PLoS Pathog. 2013;9(12):e1003784. doi: 10.1371/journal.ppat.1003784. Epub 2013 Dec 19.

Authors

Antonio Bertoletti¹, Adam J Gehring²

Affiliations

¹ Program in Emerging Viral Diseases, Duke-NUS Graduate Medical School, Singapore ; Viral Hepatitis Unit, Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research (AStar), Singapore.
² Molecular Microbiology and Immunology Department, Saint Louis University School of Medicine, St. Louis, Missouri, United States of America.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adaptive Immunity / physiology
Anti-Inflammatory Agents / therapeutic use*
Antiviral Agents / therapeutic use*
Hepatitis B virus / drug effects
Hepatitis B virus / immunology
Hepatitis B, Chronic / immunology
Hepatitis B, Chronic / therapy*
Humans
Immunity, Innate / physiology
Immunotherapy / methods*
Liver / immunology

Substances

Anti-Inflammatory Agents
Antiviral Agents

Grants and funding

The work was founded by a Singapore Translational Research Award (NMRC/STaR/013/2012) to A. Bertoletti. Adam J. Gehring is funded by Saint Louis University Startup Funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.